Saturday • April 13
CST 2:10 | EST 3:10 | MST 1:10 | PST 12:10 | GMT 07:10
Other Non-Flash Media Players
April 08, 2020

Cardiac risks of off-label drugs to treat COVID-19
Bookmark and Share
Episode Segments:
 
Cardiac risks of off-label drugs to treat COVID-19
A study published recently in Mayo Clinic Proceedings details information about potential cardiac side effects when using off-label drugs to treat COVID-19. Off-label means the drug has been approved by the Food and Drug Administration to treat a different condition. Some of the off-label drugs being used to treat COVID-19 have a risk of sudden cardiac arrest and death.

On the Mayo Clinic Q&A podcast, Dr. Michael Ackerman, a Mayo Clinic genetic cardiologist and director of the Windland Smith Rice Sudden Death Genomics Laboratory, explains how heart monitoring is important to identify at-risk patients.

Listen to this MP3 file... Download this MP3 file...